Sallie Robey Permar

Sallie Robey Permar

Wilburt C. Davison Distinguished Professor

Dr. Permar's work focuses on the development of vaccines to prevent vertical transmission of neonatal viral pathogens. She has utilized the nonhuman primate model of HIV/AIDS to characterize the virus-specific immune responses and virus evolution in breast milk and develop a maternal vaccine regimen for protection against breast milk transmission of HIV. In addition, Dr. Permar's lab has advanced the understanding of HIV-specific immune responses and virus evolution in vertically-transmitting and nontransmitting HIV-infected women, defining maternal immune responses that may protect against neonatal transmission of HIV. Importantly, Dr. Permar has established a nonhuman primate model of congenital CMV infection adn is using this model to establish the maternal immune responses that are necessary for protection against placental virus transmission. Finally, Dr. Permar is studying the impact and prevention of postnatal CMV transmission in preterm infants.

Appointments and Affiliations

  • Wilburt C. Davison Distinguished Professor
  • Adjunct Professor in the Department of Pathology
  • Associate Dean for Physician-Scientist Development
  • Affiliate, Duke Global Health Institute
  • Associate of the Duke Initiative for Science & Society
  • Member of the Duke Human Vaccine Institute

Contact Information


  • Children's Hospital Boston, 2009
  • Children's Hospital Boston, 2007
  • Ph.D. Johns Hopkins University, 2004
  • M.D. Harvard Medical School, 2004

Awards, Honors, and Distinctions

  • American Society of Clinical Investigation Inductee. ASCI. 2016
  • Young Investigator Award. Pediatric Infectious Diseases Society. 2015
  • Young Investigator Award. Society for Pediatric Research. 2014
  • Young Investigator Award. Society for Pediatrics Research. 2014
  • Presidential Early Career Awards for Scientists and Engineers. President of the United States of America. 2012

Courses Taught

  • IMMUNOL 494: Research Independent Study

In the News

Representative Publications

  • Milligan, EC; Olstad, K; Williams, CA; Mallory, M; Cano, P; Cross, KA; Munt, JE; Garrido, C; Lindesmith, L; Watanabe, J; Usachenko, JL; Hopkins, L; Immareddy, R; Shaan Lakshmanappa, Y; Elizaldi, SR; Roh, JW; Sammak, RL; Pollard, RE; Yee, JL; Herbek, S; Scobey, T; Miehlke, D; Fouda, G; Ferrari, G; Gao, H; Shen, X; Kozlowski, PA; Montefiori, D; Hudgens, MG; Edwards, DK; Carfi, A; Corbett, KS; Graham, BS; Fox, CB; Tomai, M; Iyer, SS; Baric, R; Reader, R; Dittmer, DP; Van Rompay, KKA; Permar, SR; De Paris, K, Infant rhesus macaques immunized against SARS-CoV-2 are protected against heterologous virus challenge 1 year later., Sci Transl Med, vol 15 no. 685 (2023) [10.1126/scitranslmed.add6383] [abs].
  • Schleiss, MR; Permar, SR; John, CC, What are the key pediatric public policy priorities as the COVID-19 pandemic persists?, Pediatr Res (2023), pp. 1-5 [10.1038/s41390-023-02529-x] [abs].
  • Sass, J; Awasthi, A; Obregon-Perko, V; McCarthy, J; Lloyd, AL; Chahroudi, A; Permar, S; Chan, C, A simple model for viral decay dynamics and the distribution of infected cell life spans in SHIV-infected infant rhesus macaques., Math Biosci, vol 356 (2023) [10.1016/j.mbs.2022.108958] [abs].
  • Dugdale, CM; Ufio, O; Alba, C; Permar, SR; Stranix-Chibanda, L; Cunningham, CK; Fouda, GG; Myer, L; Weinstein, MC; Leroy, V; McFarland, EJ; Freedberg, KA; Ciaranello, AL, Cost-effectiveness of broadly neutralizing antibody prophylaxis for HIV-exposed infants in sub-Saharan African settings., Journal of the International Aids Society, vol 26 no. 1 (2023) [10.1002/jia2.26052] [abs].
  • Jenks, JA; Amin, S; Sponholtz, MR; Kumar, A; Wrapp, D; Venkatayogi, S; Tu, JJ; Karthigeyan, K; Valencia, SM; Connors, M; Harnois, MJ; Hora, B; Rochat, E; McLellan, JS; Wiehe, K; Permar, SR, A single, improbable B cell receptor mutation confers potent neutralization against cytomegalovirus., Plos Pathogens, vol 19 no. 1 (2023) [10.1371/journal.ppat.1011107] [abs].